Literature DB >> 29279944

Is the whole larger than the sum of the parts? Integrated PET/MRI as a tool for response prediction.

Felix M Mottaghy1,2.   

Abstract

Mesh：

Year:  2017        PMID： 29279944     DOI： 10.1007/s00259-017-3908-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  32 in total

1.  Hypervascularity Predicts Complete Pathologic Response to Chemotherapy and Late Outcomes in Breast Cancer.

Authors:  Enida Bufi; Paolo Belli; Marialuisa Di Matteo; Michela Giuliani; Mariavalentina Tumino; Pierluigi Rinaldi; Luigia Nardone; Gianluca Franceschini; Antonino Mulé; Lorenzo Bonomo
Journal:  Clin Breast Cancer       Date:  2016-06-23       Impact factor: 3.225

2.  Association of pharmacokinetic and metabolic parameters derived using simultaneous PET/MRI: Initial findings and impact on response evaluation in breast cancer.

Authors:  Amarnath Jena; Sangeeta Taneja; Aru Singh; Pradeep Negi; Shashi Bhushan Mehta; Aashim Ahuja; Manish Singhal; Ramesh Sarin
Journal:  Eur J Radiol       Date:  2017-04-23       Impact factor: 3.528

Review 3.  Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.

Authors:  Katja Pinker; Christopher Riedl; Wolfgang A Weber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-30       Impact factor: 9.236

4.  Hybrid 18F-FDG PET/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy.

Authors:  Briete Goorts; Stefan Vöö; Thiemo J A van Nijnatten; Loes F S Kooreman; Maaike de Boer; Kristien B M I Keymeulen; Romy Aarnoutse; Joachim E Wildberger; Felix M Mottaghy; Marc B I Lobbes; Marjolein L Smidt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-10       Impact factor: 9.236

5.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.

Authors:  R L Wahl; R L Cody; G D Hutchins; E E Mudgett
Journal:  Radiology       Date:  1991-06       Impact factor: 11.105

6.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.

Authors:  I C Smith; A E Welch; A W Hutcheon; I D Miller; S Payne; F Chilcott; S Waikar; T Whitaker; A K Ah-See; O Eremin; S D Heys; F J Gilbert; P F Sharp
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

7.  [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer.

Authors:  H Minn; I Soini
Journal:  Eur J Nucl Med       Date:  1989

Review 8.  Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.

Authors:  S Lheureux; C Denoyelle; P S Ohashi; J S De Bono; F M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-10       Impact factor: 9.236

Review 9.  EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies.

Authors:  Nicolas Aide; Charline Lasnon; Patrick Veit-Haibach; Terez Sera; Bernhard Sattler; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-16       Impact factor: 9.236

Review 10.  Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review.

Authors:  Jung Han Kim
Journal:  Oncotarget       Date:  2016-09-06
View more
  3 in total

1.  Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study.

Authors:  Mariarosaria Incoronato; Anna Maria Grimaldi; Carlo Cavaliere; Marianna Inglese; Peppino Mirabelli; Serena Monti; Umberto Ferbo; Emanuele Nicolai; Andrea Soricelli; Onofrio Antonio Catalano; Marco Aiello; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-25       Impact factor: 9.236

2.  Conversion of immunohistochemical markers and breast density are associated with pathological response and prognosis in very young breast cancer patients who fail to achieve a pathological complete response after neoadjuvant chemotherapy.

Authors:  Yue Zhao; Xiaolei Wang; Yuanxi Huang; Xianli Zhou; Dongwei Zhang
Journal:  Cancer Manag Res       Date:  2019-06-20       Impact factor: 3.989

3.  3T DCE-MRI Radiomics Improves Predictive Models of Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Stefania Montemezzi; Giulio Benetti; Maria Vittoria Bisighin; Lucia Camera; Chiara Zerbato; Francesca Caumo; Elena Fiorio; Sara Zanelli; Michele Zuffante; Carlo Cavedon
Journal:  Front Oncol       Date:  2021-04-20       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.